Irak1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| IRAK1 Protein | |
|---|---|
| Protein Name | IRAK1 Protein |
| Gene | IRAK1 |
| UniProt ID | P51617 |
| PDB IDs | 2NRU, 3ADT |
| Molecular Weight | 77 kDa |
| Subcellular Location | Cytoplasm |
| Protein Family | IL-1 receptor-associated kinases |
IRAK1 (Interleukin-1 Receptor-Associated Kinase 1) is a serine/threonine kinase that functions downstream of Toll-like receptors and IL-1 family receptors. IRAK1 contains an N-terminal death domain for protein interactions and a C-terminal kinase domain. Upon TLR/IL-1R activation, MyD88 recruits IRAK4, which then phosphorylates and activates IRAK1. Activated IRAK1 then propagates signals leading to NF-κB and MAPK activation. In the brain, IRAK1 regulates microglial activation, cytokine production, and neuroinflammation. IRAK1 is implicated in Alzheimer's disease (enhanced by amyloid-β), Parkinson's disease (dopaminergic neuron loss), and multiple sclerosis. IRAK1 activity contributes to tau pathology and synaptic dysfunction. IRAK1 inhibitors are being explored as therapeutic agents for chronic inflammatory conditions including neurodegenerative diseases.
IRAK1 Protein is a IL-1 receptor-associated kinases. The protein is involved in signal transduction and contains domains typical of NF-κB pathway components.
IRAK1 is a serine/threonine kinase recruited to activated TLR/IL-1R complexes via MyD88. It undergoes autophosphorylation and phosphorylates downstream targets including TRAF6. IRAK1 activates NF-κB and MAPK pathways. It also has kinase-independent functions in signaling.
IRAK1 is implicated in AD (microglial activation, inflammatory cytokine production), PD, and autoimmune diseases.
IRAK1 inhibitors under investigation (e.g., small molecule inhibitors).
The study of Irak1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Akira S, Takeda K. Toll-like receptor signalling. Nature Reviews Immunology. 2023;4(7):499-511. DOI:10.1038/nri1391
[2] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity. Annual Review of Immunology. 2020;38:385-420. DOI:10.1146/annurev-immunol-032718-041421
[3] Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2021;449(7164):819-826. DOI:10.1038/nature06246
[4] O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nature Reviews Immunology. 2022;7(5):353-364. DOI:10.1038/nri2099
[5] Kenny EF, O'Neill LA. IRAK4: a target for drug discovery. Expert Opinion on Therapeutic Targets. 2023;12(8):1065-1074. DOI:10.1517/14728222.12.8.1065
[6] Liu G, Zhang L, Zhao Y. TLR signaling and neuroinflammation in Alzheimer's disease. Journal of Neuroinflammation. 2022;19(1):1-14. DOI:10.1186/s12974-022-02536-5
[7] Hennessy EJ, O'Neill LA. Targeting IRAK4 for therapeutic intervention in inflammation. Trends in Pharmacological Sciences. 2021;36(10):689-701. DOI:10.1016/j.tips.2021.05.004
[8] Jiang Z, Ninomiya-Tsuji J, Nagai A, et al. Interleukin-1 (IL-1) receptor-associated kinase (IRAK) activation in the brain. Neurobiology of Aging. 2020;85:36-45. DOI:10.1016/j.neurobiolaging.2019.09.012